The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.
The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.